ATA Member Groups are a great way to connect and get involved.

Members are encouraged to join one or more Special Interest Groups (SIGs). These member groups provide exclusive access to information sharing, strategic brainstorming and guidance, and policy discussions with peers, policy-makers, practitioners and administrators. SIG members network with peers, promote and support telehealth applications within their specialty, and provide authoritative guidance and information to the wider ATA membership. SIGs maintain regular communication through discussion groups and conference calls. They sponsor various activities throughout the year and meet in-person each spring at the ATA Annual Conference.

Click on a group to learn more about its mission and leadership, and to join. If you have questions or need help getting involved, checkout our Communities FAQ page.


Member only content

Decentralized Clinical Trials

19 Members
Last Activity: April 20, 2021
9 Discussions
Decentralized Clinical Trials (DCT) and hybrid trials are becoming more of a norm given the impact of the COVID-19 pandemic. By creating more patient-centered clinical trials, a decentralized approach can enhance pharma research by attracting a more diverse patient population and eliminating existing barriers to participating in research studies, including COVID-related limitations. Telehealth and remote patient monitoring (RPM) will play an important role in advancing decentralized technology-driven trials. To address this important opportunity to enable equal access to clinical trials by leveraging telehealth and virtual care technologies, the ATA has convened a member special interest group (SIG). The goals of the group include: 1. Pursue policy/advocacy to remove barriers to allow interstate work and other legislation 2. Create practice guidelines to leverage existing telehealth and RPM solutions 3. Address issues of data flow, a subset of our work on telehealth interoperability The new SIG has convened three subgroups to help achieve these goals in actionable increments, including partnership opportunities: · Policy/Advocacy o Identify the best entity to create and maintain a registry of state laws that impact conduct of DCTs o Evaluate Drug Safety & Quality Act of 2013 for any barriers to implementation of DCTs · Best Practices o Leverage existing and create new content to help research sites understand what they need to do to participate in DCTs · Data Flows o Inventory existing standards impacting DCTs o Look at ways to ensure adoption of most impactful standards Meetings are the 4th Monday of the month at 3p Eastern.